HIV extracellular tat: Myth or reality?

Current HIV Research

Volumn 13, Issue 2, 2015, Pages 90-97

  Loret, Erwann ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

HIV; HIV DNA; Reservoirs; Sanctuary; Tat; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; NEUTRALIZING ANTIBODY;

APOPTOSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CYTOTOXIC T LYMPHOCYTE; DNA TRANSCRIPTION; DRUG TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTESTINE LYMPHATIC TISSUE; LYMPHOID TISSUE; PATHOGEN CLEARANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SEROLOGY; VIREMIA; BLOOD; CD4+ T LYMPHOCYTE; EXTRACELLULAR SPACE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTESTINE; PATHOGENICITY; PHYSIOLOGY; SERODIAGNOSIS; VIROLOGY; VIRUS ACTIVATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; EXTRACELLULAR SPACE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; INTESTINES; T-LYMPHOCYTES, CYTOTOXIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS ACTIVATION;

EID: 84930983789     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666141202125643     Document Type: Article

References (53)

1. [1] Alexaki A, Liu Y, Wigdahl B. Cellular Reservoirs of HIV-1 and their Role in Viral Persistence. Curr HIV Res 2008; 5: 388-400.
2. [2] Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6
3. [3] Chun TW, Davey RT Jr, Engel D., Lane HC, Fauci, AS (1999). Re-emergence of HIV after stopping therapy. Nature 401; 10: 874-5.
4. [4] Chan CN, Dietrich I, Hosie MJ, Willet BJ. Recent developments in human immunodeficiency virus-1 latency research. J. Gen Virol 2013; 94: 917-32.
5. [5] Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV- 1 in resting CD4+ T cells. Nat Med 2003; 9: 727-8.
6. [6] Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-20.
7. [7] Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). 1983. Science 1983; 220: 868-71.
8. [8] Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLVIII) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500-3.
9. [9] Smith KA. Edward Jenner and the Small Pox Vaccine. Front Immunol 2011; 14: 2-21.
10. [10] Pang S, Shlesinger Y, Daar ES, Moudgil T, Ho DD, Chen IS. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 1992; 5: 453-60.
11. [11] Cheingsong-Popov R, Panagiotidi C, Bowcock S, et al. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ 1991, 302: 23-6.
12. [12] Caporossi AP, Bruno G, Salemi S, et al. Autoimmune Tcell response to the CD4 molecule in HIV-infected patients. Viral Immunol 1998; 11: 9-17.
13. Levy JP Is AIDS vaccine research at a turning point? J. Hum Virol. 2000 3:83-87.
14. [14] Sanou MP, De Groot AS, Murphey-Corb M, et al. HIV-1 Vaccine Trials: Evolving Concepts and Designs Open AIDS J 2012 6: 274-88.
15. [15] Richert L, Doussau A, Lelièvre JD, et al. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimized multi-arm phase I/II trial design Trials 2014, 15: 68.
16. [16] Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197: 714-20.
17. [17] Imamichi H, De Gray G, Dewar RL, et al. Lack of compartmentalization of HIV-1 quasi species between the gut and peripheral blood compartments. J Infect Dis 2011; 204: 309-14.
18. [18] Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS 2013; 3: 190-5.
19. [19] Josefsson L, Stockenstroma SV, Fariac NR, et al. The HIV- 1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. PNAS 2013; 110: 4987-96.
20. [20] Durand CM, Ghiaur G, Siliciano JD, et al. HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 2012; 205: 1014-8.
21. [21] Gray LR, Cowley D, Crespan E, et al. Reduced basal transcriptional activity of central nervous systemderived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses 2013; 2: 365-270.
22. [22] Bacchus C, Cheret A, Avettand F, et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLos One 2013; 8: e64219
23. [23] Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381: 2109-17.
24. Zolla-Pazner S A critical question for HIV vaccine development: which antibodies to induce? Science 2014; 6193: 167-8.
25. [25] Esquieu D., Péloponèse JM, Opi S et al. Discovery of a Tat HIV-1 inhibitor Through Computer-Aided Drug Design. Spectroscopy 2003; 17, 639-45.
26. [26] Narayan V, Ravindra KC, Chiaro C, Cary D, Aggarwal BB, Henderson AJ, Prabhu KS. Celastrol inhibits Tat-mediated human immunodeficiency virus (HIV) transcription and replication. J Mol Biol 2011; 410: 972-83
27. [27] Mousseau G, Clementz MA, Bakeman WN, et al. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe 2012; 12, 97-108.
28. [28] Fisher AG, Ratner L, Mitsuya H, et al. Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science 1986, 233: 655-9.
29. [29] Campbell, GR, Loret EP What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 2009; 6: 50-63.
30. [30] Loret EP, Georgel P, Johnson WC Jr, Ho PS. Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 transactivation response RNA and the binding region of Tat, the trans-acting transcriptional activator. Proc Natl Acad Sci USA 1992; 89: 9734-8.
31. [31] Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong- Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990; 345: 84-6.
32. [32] Loret EP, Vives E, Ho PS, Rochat H, Van Rietschoten J, Johnson WC Jr. Activating region of HIV-1 Tat protein: vacuum UV circular dichroism and energy minimization. Biochemistry 1991; 30: 6013-23.
33. [33] Mediouni S, Darque A, Baillat G, et al. Antiretroviral therapy does not block the secretion of the human immunodeficiency virus Tat protein. Infect Disord Drug Targets 2012; 1: 81-6.
34. [34] Chen Q, Li L, Liao W, et al. Characterization of Tat antibody responses in Chinese individuals infected with HIV-1. PLoS One 2013; 8: e60825.
35. [35] Mediouni S, Baillat G, Darque A, Ravaux I, Loret EP HIV- 1 infected patients have antibodies recognizing folded Tat. Infect Disord Drug Targets 2011; 11: 57-63.
36. [36] Bellino S, Tripiciano A, Picconi O, et al. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-years cohort study. Retrovirology 2014; 24: 11-49.
37. [37] van Baalen CA, Pontesilli O, Huisman RC, et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78: 1913-8.
38. [38] Campbell GR, Senkaali D, Watkins J, et al. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine 2007; 25: 8441-7.
39. [39] Bachani M, Sacktor N, McArthur JC, Nath A, Rumbaugh J. Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders. J Neurovirol 2013; 19: 82-8.
40. [40] Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 2007; 104: 20805-10
41. [41] Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375: 497-500.
42. [42] Rayne F, Debaisieux S, Yezid H., et al. Phosphatidylinositol-(4,5)-Bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J 2010; 8: 1348-62.
43. [43] Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117: 2791-9.
44. [44] McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410: 980-7.
45. [45] Alimonti JB, Kimani J, Matu L, et al. Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol 2006; 84: 482-5.
46. [46] Huet T, Dazza MC, Brun-Vezinet F, Roelants GE, Wain- Hobson S. A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS 1989, 3:707-15.
47. [47] Truong LX, Luong TT, Scott-Algara D, et al. CD4 cell and CD8 cell-mediated resistance to HIV-1 infection in exposed uninfected intravascular drug users in Vietnam. AIDS. 2003; 17: 1425-34.
48. [48] Saez-Cirion A, Versmisse P, Truong LX, et al. Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology 2006; 8: 81-9.
49. [49] Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: 13-23.
50. [50] Mediouni S, Darque A, Ravaux I, et al. Identification of a highly conserved surface on Tat variants. J Biol Chem 2013; 288: 19072-80.
51. [51] Rowland-Jones S, Pinheiro S, Kaul R. New insights into host factors in HIV-1 pathogenesis. Cell 2001; 104: 473-6.
52. [52] Beattie T, Rowland-Jones S, Kaul R. HIV-1 and AIDS: what are protective immune responses? J. VIH Ther 2002; 7: 35-9
53. [53] Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viraemia after treatment cessation in an infant. N Engl J Med. 2013; 369, 1828-35